Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 243

Similar articles for PubMed (Select 23479454)

1.

Prostate cancer mortality in the Finnish randomized screening trial.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.

J Natl Cancer Inst. 2013 May 15;105(10):719-25. doi: 10.1093/jnci/djt038. Epub 2013 Mar 11.

2.

The Finnish prostate cancer screening trial: analyses on the screening failures.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.

Int J Cancer. 2015 May 15;136(10):2437-43. doi: 10.1002/ijc.29300. Epub 2014 Nov 10.

PMID:
25359457
3.

Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.

Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17.

PMID:
21601352
4.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;1:CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
5.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.

6.

Results of the three rounds of the Finnish Prostate Cancer Screening Trial--the incidence of advanced cancer is decreased by screening.

Kilpeläinen TP, Auvinen A, Määttänen L, Kujala P, Ruutu M, Stenman UH, Tammela TL.

Int J Cancer. 2010 Oct 1;127(7):1699-705. doi: 10.1002/ijc.25368.

PMID:
20473861
7.

Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.

Yli-Hemminki TH, Laurila M, Auvinen A, Määttänen L, Huhtala H, Tammela TL, Kujala PM.

BJU Int. 2013 Oct;112(6):735-41. doi: 10.1111/bju.12153. Epub 2013 Jun 7.

PMID:
23746332
8.

[Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].

Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.

Prog Urol. 2009 Jul;19(7):487-98. doi: 10.1016/j.purol.2009.03.001. Epub 2009 Apr 28. French.

PMID:
19559380
9.

[Estimating standard performance measures of opportunistic screening for prostate cancer].

Leoni M, Falcini F, Ravaioli A, Foca F, Andalò G, Benini F, Dal Pozzo C, Ricci R, Naldoni C, Bucchi L.

Epidemiol Prev. 2008 Nov-Dec;32(6):285-93. Italian.

PMID:
19353962
10.

Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.

Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH; ERSPC Rotterdam Study Group.

Eur Urol. 2013 Oct;64(4):530-9. doi: 10.1016/j.eururo.2013.05.030. Epub 2013 May 25.

PMID:
23759326
11.

Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, Roobol MJ.

Eur Urol. 2014 Feb;65(2):329-36. doi: 10.1016/j.eururo.2013.08.005. Epub 2013 Aug 11.

PMID:
23954085
12.

Towards an optimal interval for prostate cancer screening.

van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J.

Eur Urol. 2012 Jan;61(1):171-6. doi: 10.1016/j.eururo.2011.08.002. Epub 2011 Aug 10.

PMID:
21840117
13.

Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Gulati R, Gore JL, Etzioni R.

Ann Intern Med. 2013 Feb 5;158(3):145-53. doi: 10.7326/0003-4819-158-3-201302050-00003.

14.

Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ.

Eur Urol. 2012 Nov;62(5):745-52. doi: 10.1016/j.eururo.2012.05.068. Epub 2012 Jun 7.

PMID:
22704366
15.

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.

de Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, Gohagan JK, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok PC, Schröder FH; European Randomized Screening for Prostate Cancer (ERSPC) Trial; International Prostate Cancer Screening Trials Evaluation Group.

Int J Cancer. 2002 Jan 10;97(2):237-44.

PMID:
11774270
16.

Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.

Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1654-60. doi: 10.1111/j.1464-410X.2012.11481.x. Epub 2012 Oct 8.

PMID:
23043563
17.

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ.

J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8.

18.
19.

Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality.

Zhu X, van Leeuwen PJ, Holmberg E, Bul M, Carlsson S, Schröder FH, Roobol MJ, Hugosson J.

J Med Screen. 2012 Sep;19(3):133-40. doi: 10.1258/jms.2012.012071.

PMID:
23093731
20.

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

van Leeuwen PJ, Otto SJ, Kranse R, Roobol MJ, Bul M, Zhu X, de Koning H, Schröder FH.

BJU Int. 2012 Jul;110(2):188-94. doi: 10.1111/j.1464-410X.2011.10811.x. Epub 2012 Jan 30.

PMID:
22288823
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk